VRTX

Vertex Pharmaceuticals Incorporated

NMS · Healthcare

$522.38

$6.04 (+1.17%)up 1.17%

24 September 2026 · delayed 15+ min

C-

Quality score72.6 / 100

Cut-offs are the grader's own: 97+ for an A+, below 60 is an F.

Vertex Pharmaceuticals Incorporated earns a C- on excellent profit margins (>20%) and strong ROE (>20%) but high debt-to-equity ratio (>2.0) and MACD bearish (negative histogram). Reasonable investment with moderate upside potential.

Model stance HOLD Suggested position 6.0% · $600.00 IQInvest estimate
Adjusted for Moderate investors, Medium-term investors 6.0% suggested allocation Change these

These change the suggested position size and the stance, not the category scores. Amount is in dollars.

IQ-VRTX-20260924engine v1 · 7-category weighted scorecard

What it is worth, depending who you ask.

Today’s price against the year it has had and the targets analysts publish. Every marker is a reported figure, not a projection of ours.

Lowest analyst target

$350.00

52-week low

$377.02

Today's price

$522.38

52-week high

$560.25

Mean analyst target

$570.32

Highest analyst target

$672.00

VRTX trades 79% of the way up its 52-week range, between $377.02 and $560.25. The mean analyst target of $570.32 is 9.2% above today's price.

Today’s price 52-week range Analyst price targets

Scored categories

Financial healthExcellent profit margins (>20%); Strong ROE (>20%); High debt-to-equity ratio (>2.0) 100.023%

Profit margin

35.00%

Net profit per unit of revenue

exceptionalWhat this means

Of every 100 units of revenue, this much survives as profit.

Margins this wide usually mean real pricing power or a moat.

Operating margin

38.05%

Before interest and tax

very highWhat this means

Profit from operations, before interest and tax, per 100 of revenue.

Typical of software and other businesses with little cost per extra sale.

Gross margin

54.96%

After the cost of goods only

highWhat this means

What is left of revenue after only the direct cost of the product.

Little marginal cost per sale, which is what lets software and pharma fund heavy R&D.

Return on equity

23.54%

Profit per unit of shareholder capital

very strongWhat this means

Profit generated per unit of shareholder capital.

Rare when sustained — check whether debt is flattering it, since borrowing shrinks the equity denominator.

Return on assets

11.93%

Profit per unit of assets

strongWhat this means

Profit generated per unit of everything the company owns.

The assets are working hard.

Debt to equity

9.77

Borrowings against equity

conservativeWhat this means

Borrowings measured against shareholder capital.

Comfortably financed.

Current ratio

3.19

Short-term assets over short-term debts

very liquidWhat this means

Short-term assets against short-term obligations.

Plenty of cover, though idle cash earns little.

Quick ratio

2.54

As above, excluding inventory

comfortableWhat this means

Short-term assets excluding inventory, against short-term debts.

Liquid assets exceed short-term obligations.

Revenue growth

12.50%

Year on year

growingWhat this means

Change in revenue against the same period last year.

A healthy expansion rate.

Earnings growth

8.00%

Year on year

modestWhat this means

Change in earnings against the same period last year.

Slow profit growth.

Revenue

$6.32B

Trailing twelve months

Free cash flow

$2.63B

Cash left after capital spending

Operating cash flow

$4.29B

Cash from the business itself

Payout ratio

0.00%

Dividends as a share of earnings

noneWhat this means

The share of earnings paid out as dividends.

All earnings are retained in the business.

Growth & momentumStrong 1-year return (37.6%) 80.022%

Return, 1 month

-5.51%

Return, 3 months

8.79%

Return, 6 months

14.82%

Return, year to date

15.54%

Return, 1 year

37.57%

Return, 3 years

45.81%

Sharpe ratio

0.80

Return earned per unit of risk

modestWhat this means

Return earned per unit of risk taken.

Below 1 is the common case; return did not strongly outpace the volatility.

Win rate

54.71%

Share of days that closed up

consistently positiveWhat this means

The share of trading days that closed higher.

More up days than most shares manage.

Average daily return

0.10%

Best day

13.23%

Worst day

-20.60%

ValuationHigh P/B ratio (6.54) 30.018%

P/E ratio

30.39

Price against trailing earnings

highWhat this means

You pay 30.39 for every 1 unit of annual earnings.

Above about 25 the market is paying up for expected growth.

Forward P/E

26.00

Price against forecast earnings

moderateWhat this means

Price against next year's *forecast* earnings.

A conventional range.

PEG ratio

1.90

P/E adjusted for growth

fairWhat this means

P/E divided by the growth rate — it asks whether the price is justified by the growth.

Between 1 and 2 price and growth are roughly in step.

Price to book

6.54

Price against balance-sheet equity

well above bookWhat this means

Price against the accounting value of the company's net assets.

Normal for asset-light businesses, where the value sits in brands and software the balance sheet never records.

Price to sales

10.52

Price against revenue

highWhat this means

Price against revenue — usable when a company has no profit yet.

The price assumes today's revenue will convert into much more profit later.

EV / EBITDA

24.51

Whole-company value against cash earnings

highWhat this means

Whole-company value, debt included, against cash earnings.

Expensive even before interest, tax and depreciation are considered.

Enterprise value

$125.00B

Market value plus debt, minus cash — the price of the whole business

Shares outstanding

253,460,924

Shares the profit is split across

TechnicalPrice well above 200-day SMA (strong uptrend); RSI in healthy range (30-70); MACD bearish (negative histogram) 80.015%

RSI (14)

50.5

Above 70 overbought, below 30 oversold

neutralWhat this means

A 0–100 momentum gauge over the last 14 sessions.

The middle band, where most trading days sit.

MACD

-1.82

Momentum against its own trend

MACD histogram

-2.85

Positive is bullish

ADX

20.3

Trend strength; above 25 is a real trend

trendingWhat this means

Trend strength, regardless of direction.

Above 25 is conventionally read as a genuine trend in force.

20-day average

$529.55

50-day average

$512.75

200-day average

$471.13

Price vs 50-day

1.88%

Price vs 200-day

10.88%

Bollinger upper

$562.56

Bollinger lower

$496.54

Average true range

12.42

Typical daily trading range

Stochastic %K

36.1

Risk4 measured figures 55.012%

Volatility, annualised

28.99%

How far it swings in a year

normalWhat this means

How far the price typically swings over a year.

A typical range for an individual share.

Beta

0.32

Moves against the wider market

steadier than the marketWhat this means

How much the price moves relative to the wider market.

Tends to move less than the index, in both directions.

Maximum drawdown

-29.07%

Worst peak-to-trough fall

significantWhat this means

The worst peak-to-trough fall in the period measured.

A serious decline, though not unusual over a multi-year window.

Risk category

High

The engine's own banding

Analyst viewAnalyst consensus: Buy; Strong analyst coverage (28 analysts) 80.010%

Consensus

Buy

What covering analysts rate it

Analysts covering

28

Mean price target

$570.32

Highest target

$672.00

Lowest target

$350.00

Implied upside

9.18%

Target against today's price

limitedWhat this means

How far the mean analyst target sits above today's price.

Little headroom to the consensus target.

Price against the S&P 500

180 trading days to 2026-09-24

VRTX is 11.5% up over the window, against 10.9% up for the S&P 500 — ahead by 0.6 points.
VRTX +11.5%S&P 500 +10.9%
Show the numbers
Sampled across the window. Both columns are rebased to 100 on 2026-01-06, so they can be compared directly.
DateCloseVRTX rebasedS&P 500 rebased
2026-01-06$468.38100.0100.0
2026-01-28$477.91102.0100.5
2026-02-19$469.27100.298.8
2026-03-12$478.13102.196.1
2026-04-02$438.7193.794.8
2026-04-24$430.2991.9103.2
2026-05-15$436.9593.3106.7
2026-06-08$442.9694.6106.6
2026-06-30$496.73106.1108.0
2026-07-22$472.57100.9108.0
2026-08-12$525.73112.2111.6
2026-09-02$556.75118.9110.4

How the score was built

Each category is scored 0–100, then multiplied by its weight. The seven contributions sum to the quality score.
CategoryScoreWeightContribution
Financial health100.023%23.0
Growth & momentum80.022%17.6
Valuation30.018%5.4
Technical80.015%12.0
Risk55.012%6.6
Analyst view80.010%8.0
ESG50.00%0.0
Quality score100%72.6

ESG is scored but carries no weight in this grade. Add ?esg=1 to the address to include it — the engine then redistributes weight across the other six, so the whole scorecard changes, not just one row.

Argue with the model

Every other grader hands you a number. This one hands you the model.

Move a slider, press Recalculate, and the grade is rebuilt from the same category scores. Nothing is hidden: the scores are the engine's, only the weighting is yours.

What each model believes. Pick one above, or set your own sliders below.
ModelThe emphasis
IQInvest defaultThe engine's own weighting: financial health 23% and performance 22% lead, valuation 18%, then technicals, risk and analysts.
Value investorPrice against worth dominates: valuation 40%, financial health 25%. Chart signals count for almost nothing.
Growth investorMomentum first: performance 40% and technicals 20%. Whether the price is fair today gets just 5%.
Sleep at nightStability over everything: risk 35% and financial health 30% together outweigh all other categories combined.
ChartistThe tape over the fundamentals: technicals 45% and performance 25%. Valuation is nearly ignored.
18%
23%
22%
12%
15%
10%
0%

These are IQInvest's own weights, totalling 100%.

Your grade

C-

72.6 / 100

Identical to the IQInvest grade.

All 65 metricsOne flat sortable table, for when you want everything at once.
Metric Category Value Source
20-day averageTechnical$529.55Yahoo Finance
200-day averageTechnical$471.13Yahoo Finance
50-day averageTechnical$512.75Yahoo Finance
52-week highMarket data$560.25Yahoo Finance
52-week lowMarket data$377.02Yahoo Finance
ADXTechnical20.3Yahoo Finance
Analysts coveringAnalyst view28Yahoo Finance
Average daily returnGrowth & momentum0.10%Yahoo Finance
Average true rangeTechnical12.42Yahoo Finance
Average volumeMarket data1,405,592Yahoo Finance
Best dayGrowth & momentum13.23%Yahoo Finance
BetaRisk0.32Yahoo Finance
Bollinger lowerTechnical$496.54Yahoo Finance
Bollinger upperTechnical$562.56Yahoo Finance
ConsensusAnalyst viewBuyYahoo Finance
Current ratioFinancial health3.19Yahoo Finance
Day highMarket data$528.89Yahoo Finance
Day lowMarket data$515.30Yahoo Finance
Debt to equityFinancial health9.77Yahoo Finance
Earnings growthFinancial health8.00%Yahoo Finance
EmployeesMarket data6,400Yahoo Finance
Enterprise valueValuation$125.00BYahoo Finance
EV / EBITDAValuation24.51Yahoo Finance
Forward P/EValuation26.00Yahoo Finance
Free cash flowFinancial health$2.63BYahoo Finance
Gross marginFinancial health54.96%Yahoo Finance
Highest targetAnalyst view$672.00Yahoo Finance
Implied upsideAnalyst view9.18%Yahoo Finance
Lowest targetAnalyst view$350.00Yahoo Finance
MACDTechnical-1.82Yahoo Finance
MACD histogramTechnical-2.85Yahoo Finance
Maximum drawdownRisk-29.07%Yahoo Finance
Mean price targetAnalyst view$570.32Yahoo Finance
OpenMarket data$515.56Yahoo Finance
Operating cash flowFinancial health$4.29BYahoo Finance
Operating marginFinancial health38.05%Yahoo Finance
P/E ratioValuation30.39Yahoo Finance
Payout ratioFinancial health0.00%Yahoo Finance
PEG ratioValuation1.90Yahoo Finance
Previous closeMarket data$516.34Yahoo Finance
Price to bookValuation6.54Yahoo Finance
Price to salesValuation10.52Yahoo Finance
Price vs 200-dayTechnical10.88%Yahoo Finance
Price vs 50-dayTechnical1.88%Yahoo Finance
Profit marginFinancial health35.00%Yahoo Finance
Quick ratioFinancial health2.54Yahoo Finance
Return on assetsFinancial health11.93%Yahoo Finance
Return on equityFinancial health23.54%Yahoo Finance
Return, 1 monthGrowth & momentum-5.51%Yahoo Finance
Return, 1 yearGrowth & momentum37.57%Yahoo Finance
Return, 3 monthsGrowth & momentum8.79%Yahoo Finance
Return, 3 yearsGrowth & momentum45.81%Yahoo Finance
Return, 6 monthsGrowth & momentum14.82%Yahoo Finance
Return, year to dateGrowth & momentum15.54%Yahoo Finance
RevenueFinancial health$6.32BYahoo Finance
Revenue growthFinancial health12.50%Yahoo Finance
Risk categoryRiskHighYahoo Finance
RSI (14)Technical50.5Yahoo Finance
Shares outstandingValuation253,460,924Yahoo Finance
Sharpe ratioGrowth & momentum0.80Yahoo Finance
Stochastic %KTechnical36.1Yahoo Finance
Volatility, annualisedRisk28.99%Yahoo Finance
VolumeMarket data926,736Yahoo Finance
Win rateGrowth & momentum54.71%Yahoo Finance
Worst dayGrowth & momentum-20.60%Yahoo Finance
Add to portfolio Compare Peers Set a price target

Yahoo Finance via yfinance · delayed 15 minutes or more